




PTC Therapeutics, Inc.
Investor Relations Department
100 Corporate Ct.
South Plainfield, NJ 07080
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: PTCT

Last Trade:	21.44
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	1.10  (+5.408%)
Day Range	20.31 - 21.65
52-Week Range	4.03 - 21.65
Volume	817,309

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 18, 2017

[PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet](#)

Jul 1, 2017

[Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference](#)

Jun 30, 2017

[PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

Jun 22, 2017

[New Analyses of Translarna™ \(ataluren\) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress](#)

Jun 6, 2017

[PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)